William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024. This is a modal window. The Playback API request failed for an ...
Provides an international platform for the discussion and resolution of ongoing controversies in breast cancer treatment. For over 35 years, it has served as a reliable resource for a wide audience of researchers and professionals. With 800K+ article downloads each year, it offers a high visibilit...
NCCN Updates Guidelines on Breast Cancer TreatmentChristin Melton
Sarah Donahue, MPH, AOCNP, cochair of the 40th Annual Miami Breast Cancer Conference nursing track, discusses the biggest updates in breast cancer from 2022. Sarah Donahue, MPH, AOCNP Updated survival data from the DESTINY-Breast03 trial (NCT03529110)1 and a landmark 4-year a...
Breast Cancer Treatment: An Update on Long-Term Outcomes by Maria Adams, MS, MPH, RD More than 1.15 million women around the world are diagnosed with breast cancer every year. How breast cancer is treated varies according to a number of factors, such as the stage of the cancer when ...
“Arguments can be made that more aggressive locoregional therapy is warranted in populations of young women with breast cancer and perhaps less aggressive therapy in the elderly,” Beadle concluded. Data on breast cancer mortality as a function of age were provided by Dr. Bircan Erbas and colleag...
Novel agent ‘highly efficient’ in HER2-positive breast cancer SAN ANTONIO — The novel antibody-drug conjugate SHR-A1811 exhibited promising antitumor activity as neoadjuvant treatment for patients with HER2-positive breast cancer, according to data presented at San Antonio Bre...
Dr Abdou on Treatment Updates From the 2023 ASCO Annual Meeting in HR+/HER2– Breast Cancer Dr Cairo on the Safety Profiles of T-DM1 vs T-DXd in HER2+ Metastatic Breast Cancer Breast Cancer Research Breakthroughs Signal Paradigm Shifts Across Disease Subsets Dr Hilton on Trastuzumab Deruxt...
EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024 EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment EP: 4.Tailoring CDK4/6 Inhibitor Treatment to Patient Needs Now Viewing EP: 5.NCCN Guidelines for Early-Stage Breast Cancer: Abemacicl...
- Overview of Triple Negative Breast Cancer - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing ...